Wojewodzki Szpital Specjalistyczny W Bialej Podlaskiej

The center is at the forefront of hematologic oncology, focusing on innovative treatments for aggressive B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Research includes evaluating novel combinations and monotherapies to enhance anti-lymphoma activity and improve patient outcomes.

• Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
• Diffuse Large B-cell Lymphoma
• Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

These studies aim to refine therapeutic strategies, offering hope for patients with limited treatment options.

Specializing in renal cell carcinoma, the center conducts pivotal trials comparing the efficacy of various drug combinations. These studies aim to improve progression-free survival and overall response rates in patients with advanced or metastatic conditions.

• Advanced or Metastatic Renal Cell Carcinoma
• Intermediate- and Poor-Risk Advanced RCC
• Clear Cell Renal Cell Carcinoma

By exploring novel therapeutic combinations, the center seeks to enhance treatment efficacy and patient quality of life.

The center is advancing research in myeloproliferative neoplasms, particularly focusing on myelofibrosis. Investigations include evaluating the efficacy of new drug combinations to manage symptoms and improve patient outcomes.

• Myelofibrosis

These efforts aim to provide more effective treatment options for patients with this challenging condition.

In the realm of oncology supportive care, the center is exploring treatments for chemotherapy-induced thrombocytopenia and cancer cachexia. These studies focus on improving the quality of life and treatment adherence for cancer patients.

• Chemotherapy-induced Thrombocytopenia
• Cancer Cachexia

Research in this area aims to mitigate the side effects of cancer treatments, enhancing patient well-being.